Proactive Investors - Run By Investors For Investors

Humanigen's therapy to reduce cancer-treatment side effects highlighted in premier hematology journal

The article entitled 'CAR-T Cell Neurotoxicity: Hope is on the Horizon' was published in 'blood', widely regarded as a premier hematology journal
Article spotlights unmet need to mitigate T cell-induced neurotoxicity using GM-CSF neutralization therapy

Humanigen Inc (OTCMKTS:HGEN) announced Friday that the official journal of the American Society of Hematology, known simply as "blood", has published an article highlighting a drug therapy the company is developing that’s designed to reduce dangerous side effects of a cancer treatment involving altered T cells.

The company said the article by Omar Ahmed entitled “CAR-T Cell Neurotoxicity: Hope is on the Horizon” was published on May 16 in blood, which is is widely regarded as a premier journal in hematology. Ahmed is Humanigen's vice president of portfolio strategy, clinical, medical and scientic affairs.

Humanigen, which is based in Burlingame, California, said the article puts the spotlight on the unmet need to mitigate T cell (CAR-T)-induced neurotoxicity using GM-CSF neutralization therapy.

READ: Humanigen unveils promising results from Ifabotuzumab Phase I study

“GM-CSF neutralization could be a next-generation strategy to potentially improve the efficacy, safety, and cost-effectiveness of CAR-T therapy,” said Humanigen CEO Cameron Durrant.

The company is developing monoclonal antibodies to improve CAR-T cancer therapies and oncology treatments. Its key drug candidate is lenzilumab, a recombinant monoclonal antibody that neutralizes a substance that promotes growth of white blood cells but is also tied to inflammations that can occur during CAR-T therapies and lead to side effects.

Humanigen said the article highlighted the potential of GM-CSF:

  • Severe neurotoxicity is a negative prognostic factor for overall survival with chimeric antigen receptor T-cell (CAR-T) therapy.
  • Prolonged exposure of corticosteroids for severe neurotoxicity may negatively influence overall survival.
  • GM-CSF neutralization identified as a potential next-generation strategy to reduce CAR-T induced neurotoxicity while simultaneously improving the efficacy and durability of the response.

Humanigen's stock recently traded down 4.4% to $1.09 a share on the OTC markets.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham


View full HGEN profile View Profile

Humanigen Inc Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use